Keros Therapeutics to Showcase Innovations at Health Conference
Keros Therapeutics to Showcase Innovations at Health Conference
During an important upcoming event, Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, will highlight its ongoing commitment to developing novel therapeutics aimed at treating conditions tied to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) protein family. This conference serves as a platform for sharing insights into their advancements in drug development.
Leadership Participation and Presentation
Jasbir S. Seehra, Ph.D., who is the Chair and Chief Executive Officer of Keros, is scheduled to engage in a fireside chat presentation. This event will take place during the Goldman Sachs 46th Annual Global Healthcare Conference, presenting an opportunity for investors and industry professionals to hear directly from Keros' leadership about their unique approaches and innovations in the biopharmaceutical space.
Event Details
The fireside chat is scheduled for June 9, 2025, at 9:20 a.m. Eastern Time. Attendees can access a live audio webcast of the session, which will be beneficial for those unable to attend in person. This presentation is a crucial moment for Keros to discuss its advancements and future directions.
Webcast Access
For those interested in watching the session, a live stream will be available online, and a recorded version will be accessible for up to 90 days post-event. This accessibility ensures that stakeholders can stay informed about Keros' strategies and projects.
About Keros Therapeutics, Inc.
Keros Therapeutics is at the forefront of biopharmaceutical innovation, focusing on conditions related to the TGF-ß protein family. The understanding of these proteins is pivotal, as they play a significant role in the growth and maintenance of various tissues such as blood, bone, skeletal muscle, and adipose tissue. Keros' innovative approach has led to the development of promising protein therapeutics designed to deliver substantial benefits to patients.
Leading Product Candidates
Keros has several product candidates under development with significant potential. Its lead candidate, KER-065, is targeting neuromuscular diseases, specifically Duchenne muscular dystrophy, which affects a large patient population. Furthermore, elritercept (KER-050), another advanced product, is being developed to address cytopenias, including anemia and thrombocytopenia, particularly in patients suffering from myelodysplastic syndrome and those with myelofibrosis. Both of these candidates represent Keros’ commitment to addressing serious health issues.
Investor Relations and Contact Information
Keros Therapeutics encourages open communication with investors and stakeholders. Those who wish to learn more can reach out to Justin Frantz, a contact for investor relations. The dedicated support line is 617-221-6042. Additionally, individuals can connect via email for faster responses regarding inquiries about the company and its initiatives.
Media Inquiries
For media-related questions or further information, the team at Joele Frank, Wilkinson Brimmer Katcher, is available for assistance. They can be contacted directly at (212) 355-4449, ensuring that media personnel can access timely and relevant information about Keros and its developments.
Frequently Asked Questions
What is Keros Therapeutics focused on?
Keros Therapeutics specializes in developing therapeutics targeting disorders linked to the dysfunctional signaling of TGF-ß proteins.
Who is presenting at the Goldman Sachs Conference?
Dr. Jasbir S. Seehra, the Chair and CEO of Keros Therapeutics, will be presenting at the conference.
How can I watch the presentation?
A live audio webcast will be available for the presentation, along with an archived replay accessible for 90 days afterward.
What are Keros' leading product candidates?
Keros’ lead product candidate is KER-065 for neuromuscular diseases, with elritercept (KER-050) designed for cytopenias.
Who can I contact for investor relations?
Justin Frantz is the primary contact for investor relations, and he can be reached at 617-221-6042.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.